tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sandoz Targets ‘Golden Decade’ as Patent Cliff Opens USD 600 Billion Generics and Biosimilars Opportunity
PremiumCompany AnnouncementsSandoz Targets ‘Golden Decade’ as Patent Cliff Opens USD 600 Billion Generics and Biosimilars Opportunity
1M ago
Sandoz price target raised to CHF 70 from CHF 55 at Barclays
Premium
The Fly
Sandoz price target raised to CHF 70 from CHF 55 at Barclays
1M ago
Sandoz initiated with a Neutral at Oddo BHF
Premium
The Fly
Sandoz initiated with a Neutral at Oddo BHF
2M ago
Sandoz Launches First FDA-Approved MS Biosimilar in US
PremiumCompany AnnouncementsSandoz Launches First FDA-Approved MS Biosimilar in US
3M ago
Sandoz Expands Oncology Portfolio with Global License for Pertuzumab Biosimilar
Premium
Company Announcements
Sandoz Expands Oncology Portfolio with Global License for Pertuzumab Biosimilar
3M ago
Sandoz price target raised to CHF 60 from CHF 55 at JPMorgan
Premium
The Fly
Sandoz price target raised to CHF 60 from CHF 55 at JPMorgan
3M ago
Sandoz price target raised to CHF 49 from CHF 41 at Berenberg
PremiumThe FlySandoz price target raised to CHF 49 from CHF 41 at Berenberg
4M ago
Sandoz price target raised to CHF 55 from CHF 46 at JPMorgan
Premium
The Fly
Sandoz price target raised to CHF 55 from CHF 46 at JPMorgan
5M ago
Sandoz reaches agreement with Regeneron over patent litigation
Premium
The Fly
Sandoz reaches agreement with Regeneron over patent litigation
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100